Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-306 vs salvage chemotherapy in IDH1/IDH2-mutated relapsed/refractory AML
ChiCTR2500100549Phase 3Recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ranosidenib in acute myeloid leukemia (AML) (10 cohorts), sponsored by Peking University People's Hospital. Primary endpoint: Overall Survival (OS). Started Apr 2025; status: recruiting.
02
Drugs
ranosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2500100549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500100549.